In Phase C, members will acquire ABBV-744 and oral navitoclax. In Phase D, contributors will acquire ABBV-744 and ruxolitinib. Contributors will get treatment until finally disorder progression or even the individuals are not able to tolerate the study drugs. Celastrol was recognized as being a Myb inhibitor that suppressed C/EBPβ https://abbv-744-clinical-trial-p12457.glifeblog.com/31127091/the-smart-trick-of-abbv-744-preclinical-studies-and-results-that-nobody-is-discussing